Healthdirect Australia is not responsible for the content and advertising on the external website you are now entering.
Brand name: Harvoni TM
Active ingredients: ledipasvir + sofosbuvir
What it is used for
HARVONI (ledipasvir/sofosbuvir fixed-dose combination) is indicated for the treatment of chronic hepatitis C (CHC) infection in adults. (see PRECAUTIONS and CLINICAL TRIALS sections for information on the available data for HCV patients of each genotype, see DOSAGE AND ADMINISTRATION section for recommended regimens and treatment durations for different patient subgroups).
How to take it
The way to take this medicine is: Oral. This medicine is taken by mouth.
- Store below 30 degrees Celsius
- Store at room temperature
- Shelf lifetime is 72 Months.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
Film coated, orange, diamond shaped tablet with "GSI" on one side and "7985" on the other side
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Is this medicine subsidised?
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on February 1, 2021. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
Pregnant or planning a pregnancy?
For the active ingredient ledipasvir + sofosbuvir
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Download leaflet
For side effects, taking other medicines and more
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems
Need more information?
These trusted information partners have more on this topic.
Top results
The hazards of rapid approval of new drugs | Issue 1 | Volume 39 | Australian Prescriber
The attempt to speed up drug registration approvals could be detrimental for the appropriateness and safety of new medicines in Australia.
Read more on Australian Prescriber website
Top results
The hazards of rapid approval of new drugs | Issue 1 | Volume 39 | Australian Prescriber
The attempt to speed up drug registration approvals could be detrimental for the appropriateness and safety of new medicines in Australia.
Read more on Australian Prescriber website
